Can-Fite BioPharma Secures Canadian Patent Allowance For A3 Adenosine Receptor Ligand Targeting Fat Loss

Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market

Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled "An A3 adenosine receptor ligand for use for achieving a fat loss effect.

The patent covers the use of Namodenoson, Can-Fite's orally bioavailable A3 adenosine receptor (A3AR) agonist, for reducing fat mass and body weight, providing intellectual property protection in Canada for its development as an anti-obesity therapy.